← All diseases

Disease Atlas / Disease detail

Prostate cancer

An educational overview concisely summarizing the definition, risk factors, symptoms, diagnosis, management, and interpretation of evidence for prostate cancer.

prostate cancer · cancer of prostate gland · hereditary prostate cancer · malignant neoplasm of prostate · malignant neoplasm of prostate gland · malignant neoplasm of the prostate · malignant prostate gland neoplasm · malignant prostate neoplasm · malignant prostate tumor · malignant prostate tumour · malignant tumor of prostate · malignant tumor of the prostate · malignant tumour of prostate · malignant tumour of the prostate · prostate cancer, familial · prostate gland cancer · prostate neoplasm · prostatic neoplasm · tumor of the prostate · tumour of the prostate

MONDO:0008315Public QA completeSource-bound · 4

Disease at a glance

Start with the essentials, then explore the patient and research views.

Public revision · 8bb64a26257f

Disease category
Prostate cancer is a malignant tumor that begins in the prostate cells. The prostate is a gland of the male reproductive system located below the bladder that produces part of the semen.
Key mechanism
The exact cause has not been determined, but changes in genetic material (DNA) are involved; some changes are inherited and others occur during a lifetime.
Main causes/related factors
Abnormal cells proliferate uncontrollably, and depending on the biological characteristics of the tumor, they may remain within the prostate or spread to surrounding tissues and other areas.
Representative patterns
When symptoms appear, there may be a weakened urine stream, difficulty initiating urination, frequent urination/nocturia, hematuria/hematospermia, or persistent lower back, hip, or pelvic pain.
Individual differences
The risk increases with age, and the risk and progression may vary depending on a family history of prostate cancer in close relatives and the background of specific population groups.
Diagnosis
In the early stages, there may be no symptoms; some prostate cancers grow very slowly, but others can progress rapidly and metastasize, causing serious problems.
Management
Evaluation combines PSA blood tests, digital rectal examination, and imaging studies such as ultrasound and MRI based on medical history and physical examination, and suspicious lesions are generally confirmed via prostate biopsy.
Treatment/Research Status
An elevated PSA can occur due to causes other than prostate cancer, and urinary symptoms can also appear in benign prostate diseases; therefore, a definitive diagnosis cannot be made based on a single test or symptom alone.
Read Evidence
Management plans are determined by combining observation, local treatment, and systemic treatment, while considering the extent of the cancer, expected growth rate, symptoms, age, overall health, and individual goals.
Key Precautions
Options such as observation, surgery, radiation therapy, hormone therapy, chemotherapy, targeted therapy, and immunotherapy are presented as treatment choices, and the selection varies depending on the stage and individual condition.

For patients and families

A structured guide for understanding the disease and preparing for clinical conversations.

At a Glance

Prostate cancer is a malignant tumor that begins in the prostate cells. The prostate is a gland of the male reproductive system located below the bladder that produces part of the semen.

When symptoms appear, there may be a weakened urine stream, difficulty initiating urination, frequent urination/nocturia, hematuria/hematospermia, or persistent lower back, hip, or pelvic pain.

How the disease works

The exact cause has not been determined, but changes in genetic material (DNA) are involved; some changes are inherited and others occur during a lifetime.

Abnormal cells proliferate uncontrollably, and depending on the biological characteristics of the tumor, they may remain within the prostate or spread to surrounding tissues and other areas.

Variations in presentation among individuals

The risk increases with age, and the risk and progression may vary depending on a family history of prostate cancer in close relatives and the background of specific population groups.

The broad framework of diagnosis and management

In the early stages, there may be no symptoms; some prostate cancers grow very slowly, but others can progress rapidly and metastasize, causing serious problems.

Evaluation combines PSA blood tests, digital rectal examination, and imaging studies such as ultrasound and MRI based on medical history and physical examination, and suspicious lesions are generally confirmed via prostate biopsy.

Current status of treatment

An elevated PSA can occur due to causes other than prostate cancer, and urinary symptoms can also appear in benign prostate diseases; therefore, a definitive diagnosis cannot be made based on a single test or symptom alone.

Management plans are determined by combining observation, local treatment, and systemic treatment, while considering the extent of the cancer, expected growth rate, symptoms, age, overall health, and individual goals.

Options such as observation, surgery, radiation therapy, hormone therapy, chemotherapy, targeted therapy, and immunotherapy are presented as treatment choices, and the selection varies depending on the stage and individual condition.

How to read clinical trials

In follow-up, test results and changes in symptoms must be interpreted over time; registered clinical trials only demonstrate the existence of research and do not prove efficacy, approval, or standard of care; the Pillars4Life Trial in this packet is recorded as a completed study with unpublished results.

Points to verify during clinical consultations

In clinical practice, it is necessary to confirm urinary/sexual/pain symptoms, PSA and imaging/biopsy results, family history and medications taken, cancer stage/risk, and the expected effects and side effects of observation and treatment.

Medical Guidance

This material is for general educational information only and cannot replace individual diagnosis or treatment, nor be used as individual clinical guidelines.

Evidence and sources

A trial registry status does not establish efficacy or regulatory approval.